← Back to Search

Monoclonal Antibodies

SIACI of Erbitux and Bevacizumab for Diffuse Intrinsic Pontine Glioma

Phase 1 & 2
Waitlist Available
Led By Jeffery Greenfield, MD PhD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing the safety and effectiveness of a treatment for brain tumors in children. The treatment involves delivering drugs directly to the brain through a catheter.

Eligible Conditions
  • Diffuse Intrinsic Pontine Glioma
  • Fibrillary Astrocytoma
  • Brain Stem Glioma
  • Anaplastic Astrocytoma
  • Oligodendroglioma-Astrocytoma
  • Pilomyxoid Astrocytoma
  • Glioblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Composite Overall Response Rate (CORR)
Median Overall Survival (OS)
Secondary outcome measures
Median Progression-free Survival (PFS)
Number of Treatment Emergent Adverse Events

Trial Design

1Treatment groups
Experimental Treatment
Group I: SIACI of Erbitux and BevacizumabExperimental Treatment1 Intervention
Superselective Intraarterial Cerebral Infusion (SIACI) of Erbitux (200 mg/m^2) and Bevacizumab (15 mg/kg)

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,054 Previous Clinical Trials
1,316,296 Total Patients Enrolled
Jeffery Greenfield, MD PhDPrincipal InvestigatorWeill Medical College of Cornell University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
2013. "Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01884740.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top